Dr. Overton Can Give the FDA the Pro-Life Reset It Needs

President Donald Trump has done more to advance the pro-life cause than any president in modern American history. His Supreme Court appointments helped overturn Roe v. Wade, he became the first sitting president to address the March for Life in person, and he repeatedly affirmed that every child is a precious gift from God.

His nomination of Dr. Heidi Overton to lead the Food and Drug Administration (FDA) offers another reason for encouragement. Dr. Overton is not someone whose views on life are in question. She has called abortion corrosive to women, children and society, has criticized the spread of mail-order chemical abortion, and has argued that public policy should protect both the mother and her unborn child.

SUPPORT LIFENEWS! If you want to help fight abortion, please donate to LifeNews.com!

It is encouraging to see someone with such a strong pro-life record nominated to lead the FDA. I am eager to hear how she plans to turn that record into action at an agency that urgently needs a new direction.

For too long, the FDA has failed to confront the full consequences of its policies on mifepristone. The abortion drug has become central to the abortion industry’s post-Roe strategy, particularly as pills prescribed through telehealth and shipped through the mail cross state lines and reach women without the protections that come with an in-person medical examination. Even as questions mounted about the safety of dispensing mifepristone through this expanding mail-order system, FDA leadership unfortunately failed to demonstrate the urgency this issue demands.

Commissioner Marty Makary promised a review of real-world evidence concerning these questions, including whether the drug could be safely dispensed under the loosened safeguards adopted during the Biden administration. But he left office without resolving them. He also elevated Vinay Prasad, an outspoken supporter of abortion rights, and pushed for his return after an earlier departure. These decisions deepened concern that the FDA remained disconnected from President Trump’s pro-life commitments.

Dr. Overton now has an opportunity to change that.

She will inherit that same FDA review that was announced nearly a year ago and still has no public completion date. Reports also indicated that prior agency leadership sought to delay releasing its conclusions until after the midterm elections, creating the troubling appearance that questions of political timing were superseding those involving the lives of women and unborn children. President Trump’s nomination of Dr. Overton gives the FDA an opportunity to move beyond that misjudgment, complete an honest review and act on what it finds.

A new report from Senate Health, Education, Labor and Pensions Committee Chairman Bill Cassidy also underscores why delay is no longer acceptable. His investigation found serious gaps in the oversight of companies involved in distributing mifepristone. It also found that reports of adverse events fell dramatically after the federal government ended mandatory reporting of nonfatal complications, raising serious questions about what we are now not being told about the drug.

That should concern every American, regardless of where they stand politically. The FDA cannot reliably assess the drug’s risks when many serious nonfatal complications are no longer required to be reported. Nor should it ignore cases in which men have obtained mifepristone online and used the drugs to coerce pregnant women into having an abortion or administered them without their knowledge to the same effect, or the ease with which mail-order distribution can circumvent state laws intended to protect women and unborn children.

Dr. Overton has already written that policy should halt the normalization of abortion-on-demand and recognize the risks chemical abortion poses to women. Her confirmation process provides an important opportunity for her to explain how those principles will guide her leadership. Senators should invite her to lay out clearly how she will bring the existing review to a conclusion, and whether the FDA will restore meaningful safeguards upon abortion drugs like mifepristone instead of continuing the regulatory drift of recent years.

The thousands of pastors and faith leaders I work with understand that personnel is policy. They remember President Trump’s historic pro-life victories and recognize that the end of Roe was not the end of our responsibility. Protecting life also requires vigilance throughout the federal agencies whose decisions can advance or undermine a culture of life.

Dr. Overton’s nomination marks a chance for a genuine reset at the FDA. Her confirmation hearing will offer a chance to show what that reset will mean and to lay out a clear, life-affirming vision for the FDA. Pro-life leaders are encouraged by the opportunity ahead and will be watching closely.

LifeNews Note: Chad Connelly is the Founder & CEO of Faith Wins, an organization dedicated to helping faith leaders leverage their influence and impact within the governmental and political arena.